RANBP2 and inflammatory myofibroblastic tumor: Among them, huntingdon-interacting protein (HIP1)-ALK and RAN-binding protein 2 (RANBP2)-ALK, which have been reported to exist in NSCLC and inflammatory myofibroblastic tumors, respectively, show clinical responses to crizotinib [25, 26].